Login to Your Account

Financings Roundup

Ambit Cuts Price, Ups Shares; $65M IPO to Fund Quizartinib

By Jennifer Boggs
Managing Editor

Friday, May 17, 2013
Despite losing a potentially lucrative FLT3 inhibitor partnership with Astellas Pharma Inc. barely two months ago, Ambit Biosciences Corp. forged ahead with its initial public offering (IPO). The San Diego-based biotech priced about 8.1 million shares at $8 apiece for gross proceeds of about $65 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription